Perioperative Apalutamide in High-Risk Localized Prostate Cancer

Key Points

• To evaluate the efficacy of perioperative apalutamide in improving outcomes for patients with high-risk localized prostate cancer.
• Randomized trial design with a focus on perioperative administration of apalutamide
• Inclusion of high-risk localized prostate cancer patients
• Assessment of clinical outcomes including survival rates and biomarkers.
• Apalutamide significantly improved disease-free survival at 36 months compared to control (HR 0.65, 95% CI 0.50-0.85, p=0.002)
• Lower rates of progression observed in the apalutamide group with significant reductions in adverse events.
• Positive changes noted in biomarkers associated with tumor response.